PTCT
insider transactionsPTC THERAPEUTICS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-115.7K
0 buy · 115.7K sell
Net value · 90d
-$7.0M
$0 in · $7.0M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
20
0 buy · 115.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
CHIEF BUSINESS OFFICER · 10b5-1
$0
17.6K sh
Own -100%
-
Sell·S
CHIEF BUSINESS OFFICER · 10b5-1
$1.3M
17.6K sh · $75.00
Own -19%
-
Exercise·M
CHIEF BUSINESS OFFICER · 10b5-1
$316.4K
17.6K sh · $18.01
Own +24%
-
Sell·S
CHIEF BUSINESS OFFICER · 10b5-1
$278.3K
3.7K sh · $75.00
Own -5%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$0
2.8K sh
Own +17%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$33.1K
456 sh · $72.67
Own -0%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$169.8K
2.4K sh · $72.08
Own -2%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$72.2K
2.8K sh · $25.69
Own +3%
-
Sell·S
Matthew B. Klein KEY
CHIEF EXECUTIVE OFFICER · 10b5-1
$186.4K
2.6K sh · $72.46
Own -1%
-
Sell·S
Matthew B. Klein KEY
CHIEF EXECUTIVE OFFICER · 10b5-1
$153.5K
2.1K sh · $73.08
Own -1%
-
Sell·S
Matthew B. Klein KEY
CHIEF EXECUTIVE OFFICER · 10b5-1
$527.7K
7.2K sh · $73.08
Own -2%
-
Sell·S
Matthew B. Klein KEY
CHIEF EXECUTIVE OFFICER · 10b5-1
$49.6K
679 sh · $73.06
Own -0%
-
Grant·A
Matthew B. Klein KEY
CHIEF EXECUTIVE OFFICER · 10b5-1
$0
12.5K sh
Own +3%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$0
800 sh
Own +2%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$0
2.7K sh
Own +7%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$47.6K
600 sh · $79.28
Own -1%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$15.6K
200 sh · $78.00
Own -0%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$37.2K
800 sh · $46.54
Own +1%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$150.7K
1.9K sh · $79.31
Own -2%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$65.7K
840 sh · $78.23
Own -1%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$127.5K
2.7K sh · $46.54
Own +3%
-
Sell·S
Matthew B. Klein KEY
CHIEF EXECUTIVE OFFICER · 10b5-1
$202.1K
2.9K sh · $70.91
Own -1%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$0
2.3K sh
Own +50%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$100.6K
1.4K sh · $69.75
Own -1%
-
Sell·S
EXEC. VP AND CLO · 10b5-1
$56.6K
822 sh · $68.91
Own -1%
-
Exercise·M
EXEC. VP AND CLO · 10b5-1
$89.3K
2.3K sh · $39.42
Own +2%
-
Sell·S
EVP & CHIEF MEDICAL OFFICER · 10b5-1
$56.4K
829 sh · $67.99
Own -1%
-
Sell·S
CHIEF TECHNICAL OPS OFFICER · 10b5-1
$5.6K
80 sh · $70.30
Own -0%
-
Sell·S
CHIEF TECHNICAL OPS OFFICER · 10b5-1
$870.8K
12.5K sh · $69.50
Own -17%
-
Sell·S
CHIEF TECHNICAL OPS OFFICER · 10b5-1
$2.7M
39.4K sh · $68.89
Own -35%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Eric Pauwels 10b5-1 | Sell S | 17.6K | $0 |
| Jun 10, 2026 | Eric Pauwels 10b5-1 | Sell S | 17.6K | $1.3M |
| Jun 10, 2026 | Eric Pauwels 10b5-1 | Exercise M | 17.6K | $316.4K |
| Jun 10, 2026 | Eric Pauwels 10b5-1 | Sell S | 3.7K | $278.3K |
| May 15, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 2.8K | $0 |
| May 15, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 456 | $33.1K |
| May 15, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 2.4K | $169.8K |
| May 15, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 2.8K | $72.2K |
| May 14, 2026 | Matthew B. Klein KEY 10b5-1 | Sell S | 2.6K | $186.4K |
| May 14, 2026 | Matthew B. Klein KEY 10b5-1 | Sell S | 2.1K | $153.5K |
| May 14, 2026 | Matthew B. Klein KEY 10b5-1 | Sell S | 7.2K | $527.7K |
| May 14, 2026 | Matthew B. Klein KEY 10b5-1 | Sell S | 679 | $49.6K |
| May 13, 2026 | Matthew B. Klein KEY 10b5-1 | Grant A | 12.5K | $0 |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 800 | $0 |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 2.7K | $0 |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 600 | $47.6K |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 200 | $15.6K |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 800 | $37.2K |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 1.9K | $150.7K |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 840 | $65.7K |
| May 8, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 2.7K | $127.5K |
| Apr 21, 2026 | Matthew B. Klein KEY 10b5-1 | Sell S | 2.9K | $202.1K |
| Apr 6, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 2.3K | $0 |
| Apr 6, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 1.4K | $100.6K |
| Apr 6, 2026 | Mark Elliott Boulding 10b5-1 | Sell S | 822 | $56.6K |
| Apr 6, 2026 | Mark Elliott Boulding 10b5-1 | Exercise M | 2.3K | $89.3K |
| Apr 2, 2026 | Lee Scott Golden 10b5-1 | Sell S | 829 | $56.4K |
| Apr 1, 2026 | Neil Gregory Almstead 10b5-1 | Sell S | 80 | $5.6K |
| Apr 1, 2026 | Neil Gregory Almstead 10b5-1 | Sell S | 12.5K | $870.8K |
| Apr 1, 2026 | Neil Gregory Almstead 10b5-1 | Sell S | 39.4K | $2.7M |
About PTCT insider trading
This page tracks insider transactions for PTC THERAPEUTICS, INC. (PTCT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.